CLINICAL TRIALS PROFILE FOR SYMBYAX
✉ Email this page to a colleague
All Clinical Trials for SYMBYAX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00339079 ↗ | Treatment of Hypochondriasis With CBT and/or SSRI | Completed | National Institute of Mental Health (NIMH) | Phase 1/Phase 2 | 2006-06-01 | This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis. |
| NCT00339079 ↗ | Treatment of Hypochondriasis With CBT and/or SSRI | Completed | Brigham and Women's Hospital | Phase 1/Phase 2 | 2006-06-01 | This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis. |
| NCT00489593 ↗ | Olanzapine in Patients With Advanced Cancer and Weight Loss | Completed | M.D. Anderson Cancer Center | Phase 1 | 2006-10-01 | The goal of this clinical research study is to find the highest tolerable dose of the drug Olanzapine that can be given to patients with advanced cancer who are experiencing weight loss. Researchers want to find out if Olanzapine can help decrease weight loss in patients who are experiencing it because of cancer. How this drug affects performance status, cancer-related symptoms, and nutritional status in patients with advanced cancer will also be studied. |
| NCT00512291 ↗ | Subcutaneous Olanzapine for Hyperactive or Mixed Delirium | Completed | M.D. Anderson Cancer Center | N/A | 2005-06-01 | The objective of this study is to determine the tolerability and safety of olanzapine administered as a subcutaneous injection to hospitalized patients with hyperactive or mixed delirium. |
| NCT00844857 ↗ | A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression | Completed | Eli Lilly and Company | Phase 4 | 2009-04-01 | The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. - Can this study drug make children with bipolar depression feel better? - Does this study drug work better than a placebo (sugar pill)? - Does this study drug cause side effects in children who take it? - Is this drug safe to use in children? (The study drug is a mixture of olanzapine and fluoxetine) |
| NCT00958568 ↗ | A Study in Relapse Prevention of Treatment-Resistant Depression | Completed | Eli Lilly and Company | Phase 3 | 2009-08-01 | The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when used to treat patients with Treatment Resistant Depression for a long time (up to 47 weeks), to determine whether olanzapine and fluoxetine combination or fluoxetine alone is better to treat Treatment Resistant Depression when treated for a long time (up to 47 weeks) and to assess the quality of life during treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SYMBYAX
Condition Name
Clinical Trial Locations for SYMBYAX
Trials by Country
Clinical Trial Progress for SYMBYAX
Clinical Trial Phase
Clinical Trial Sponsors for SYMBYAX
Sponsor Name
